Free Trial
NASDAQ:FBLG

FibroBiologics Q1 2025 Earnings Report

FibroBiologics logo
$0.58 +0.05 (+9.02%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.58 -0.01 (-1.10%)
As of 08/8/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Earnings Documents

FibroBiologics Earnings Headlines

HC Wainwright Lifts Earnings Estimates for FibroBiologics
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
FibroBiologics' (FBLG) "Buy" Rating Reiterated at HC Wainwright
FibroBiologics (NASDAQ:FBLG) Given "Buy" Rating at D. Boral Capital
FBLG: Closes Third Tranche of $5M…
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat